French pharmaceutical company Servier is making a big bet that a tiny drug-loaded implantable pump being developed by a Boston-based startup will transform the global market for patients with diabetes. . Servier has agreed to pay Intarcia Therapeutics Inc. $171 million up front, with potential additional payments that could increase the total to more than $1 billion, for rights to co-develop the device for most markets outside the U.S., the companies said. Closely held Intarcia retains full rights to the treatment for the U.S....
  